(Total Views: 300)
Posted On: 10/12/2019 7:46:04 AM
Post# of 154852
Some statistics of HIVDR ( HIV drug resistant ).....
16% of of HIV patients are HIVDR in Angola,
13% in Argentina
10% in Botswania.
22% In Cuba
15% in Mexico
16% in Papua New Guinea
14% in South Africa.
Also dramatic increase of MDR ( multi drug resistant ) in HIV positive children , egz , infants in Zimbabwe , between 2007 and 2014 it went up from 21.5% to 40.2%....Mostly due to increase of HIVDR mothers .
In South Africa 63.7% of children living with HIV under 18 years of age are drug resistant .
There are about 38 mill HIV positive patients globally , in 2016 , 940,000 died due to AIDS related problems , those must be in majority drug resistant patients .
about 16,000 died in USA ...
I hope that our FDA knows those statistics , because if about 1 mill people dying yearly , from problem when often Leronlimab could help , and we waiting every few months for different reasons for 3 years now to be approve ,
this is a very big problem...
Why we were not approved with 81% efficacy with 350 mg dose , and after that play with different dose ????
This I will never understand.
IMO as always.
16% of of HIV patients are HIVDR in Angola,
13% in Argentina
10% in Botswania.
22% In Cuba
15% in Mexico
16% in Papua New Guinea
14% in South Africa.
Also dramatic increase of MDR ( multi drug resistant ) in HIV positive children , egz , infants in Zimbabwe , between 2007 and 2014 it went up from 21.5% to 40.2%....Mostly due to increase of HIVDR mothers .
In South Africa 63.7% of children living with HIV under 18 years of age are drug resistant .
There are about 38 mill HIV positive patients globally , in 2016 , 940,000 died due to AIDS related problems , those must be in majority drug resistant patients .
about 16,000 died in USA ...
I hope that our FDA knows those statistics , because if about 1 mill people dying yearly , from problem when often Leronlimab could help , and we waiting every few months for different reasons for 3 years now to be approve ,
this is a very big problem...
Why we were not approved with 81% efficacy with 350 mg dose , and after that play with different dose ????
This I will never understand.
IMO as always.
(2)
(0)
